Qualigen Therapeutics, Inc. (QLGN)

$1.5

-0.01 (-0.66%)
Rating:
Recommendation:
-
Symbol QLGN
Price $1.5
Beta -0.056
Volume Avg. 0.03M
Market Cap 6.317M
Shares () -
52 Week Range 1.415-16.7
1y Target Est -
DCF Unlevered QLGN DCF ->
DCF Levered QLGN LDCF ->
ROE -97.97% Strong Sell
ROA -60.49% Strong Sell
Operating Margin -
Debt / Equity 57.97% Buy
P/E -2.75 Sell
P/B 0.49 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest QLGN news


Mr. Michael S. Poirier
Healthcare
Biotechnology
NASDAQ Capital Market

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.